SureGuardTM WDG Herbicide

SECTION 2: Hazards identification

EMERGENCY OVERVIEW CAUTION: - FOR RESEARCH AND DEVELOPMENT PURPOSES ONLY - TO BE USED ONLY UNDER THE DIRECT SUPERVISION OF A TECHNICALLY QUALIFIED INDIVIDUAL - HARMFUL IF INHALED OR ABSORBED THROUGH THE SKIN - AVOID BREATHING DUST OR SPRAY MIST - AVOID CONTACT WITH EYES, SKIN OR CLOTHING - KEEP OUT OF REACH OF CHILDREN

Potential health effects

Acute Toxicity (Primary Routes of Exposure) Signs and Symptoms of Systemic Effects: No signs or symptoms occurred in animals exposed to high oral or dermal doses of flumioxazin. Exposure to very high concentrations in the air resulted in breathing difficulties, decreased activity and some changes in the tissues of the respiratory system. Eye: This product is expected to cause brief and/or minor eye irritation. The degree of injury will depend on the amount and duration of contact and the speed and thoroughness of the first aid treatment. The expected adverse health effects resulting from an exposure may include redness and possible swelling. Skin: This product is expected to cause brief and/or minor irritation. The degree of injury will depend on the amount and duration of contact and the speed and thoroughness of the first aid treatment. The expected adverse health effects resulting from an exposure may include redness and possibly some minor swelling. This product is not expected to cause allergic skin reactions. This product has been shown to be slightly toxic when absorbed through the skin. The degree of injury will depend on the amount of material inhaled and the speed and thoroughness of the first aid treatment. The expected adverse systemic health effects are described above. Ingestion: This product has been shown to be minimally toxic when ingested. The degree of injury will depend on the amount of material ingested and the speed and thoroughness of the first aid treatment. The expected adverse systemic health effects are described above. Inhalation: This product has been shown to be slightly toxic when inhaled. The degree of injury will depend on the amount of material inhaled and the speed and thoroughness of the first aid treatment. The expected adverse systemic health effects are described above. EMERGENCY TELEPHONE #: (800) 892-0099 NDA – No Data Available NA – Not Applicable MSDS Number: 0187 Revision Number: 0 Revision Date: 08/14/2001 Exposure to high concentrations may result in respiratory irritation. Signs and symptoms may include, but not be limited to, nasal discharge, sore throat, coughing and difficulty in breathing. Chronic Toxicity (Including Cancer): Repeated exposures to flumioxazin technical in animals have produced anemia and other blood formation changes, organ weight changes and changes in blood chemistry. Flumioxazin technical did not produce cancer in lifetime feeding studies in laboratory animals. This material contains a small amount of crystalline silica. Repeated inhalation of large amounts of silica dust over an extended period of time may result in a progressive, disabling disease, silicosis. Symptoms include shortness of breath, chest pain and reduced lung function. The International Agency for Research on Cancer (IARC) has determined that respirable crystalline silica is a probable carcinogen. The National Toxicology Program (NTP) classifies respirable crystalline silica as a substance that may reasonably be anticipated to be a carcinogen. Teratology (Birth Defects) Information: Birth defects were produced in the offspring of female rats exposed to flumioxazin technical. No effects were observed in rabbits. Reproduction Information: Reproductive effects were observed in rats exposed to flumioxazin technical. Potentially Aggravated Conditions: Individuals with anemia or preexisting diseases of the blood may have increased susceptibility to the toxicity of excessive exposures. For complete discussion of the toxicology data from which this evaluation was made, refer to Section 11. For Regulatory Information, refer to Section 15.